Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.99 -2.92

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.94

Max

4.03

Galvenie mērījumi
By Trading Economics
Ienākumi	-42M -78M
EPS	-0.59
Darbinieki	106
EBITDA	-42M -77M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+121.3% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	25M 356M
Iepriekšējā atvēršanas cena	6.91
Iepriekšējā slēgšanas cena	3.99

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. sept. 23:51 UTC

Core PPI Release on September 10 Expected to Show 0.3% Increase Amid Strong Employment Data and Speculation of Fed Rate Hikes Due to Inflation Concerns.

2026. g. 5. sept. 23:41 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% in August Amid Strong Job Growth and Heightened Interest Rate Hike Speculation

2026. g. 5. sept. 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid ECB Tightening and Investor Caution Ahead of September Release

2026. g. 5. sept. 23:01 UTC

Australia's Consumer Confidence Set for Release Amid Mixed Economic Signals and Global Uncertainties

2026. g. 5. sept. 22:51 UTC

Mexico's Inflation Rate Release on September 9, 2026, Sparks Market Concerns Amid Strong U.S. Jobs Data and Potential Interest Rate Adjustments.

2026. g. 5. sept. 22:51 UTC

Mexico's August 2026 Inflation Rate Release Expected to Influence Monetary Policy and Investor Confidence Amid Easing Trends.

2026. g. 5. sept. 22:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid positive market trends and strong U.S. job growth influencing economic outlook.

2026. g. 5. sept. 22:41 UTC

U.S. MBA 30-Year Mortgage Rate Set to Rise Amid Strong Job Growth and Inflation Concerns, Influencing Fed Interest Rate Expectations

2026. g. 5. sept. 22:31 UTC

Brazil's Central Bank readout on interest rates set for September 8, 2026, amid global economic influences and heightened speculation in financial markets.

2026. g. 5. sept. 22:21 UTC

Japan's Q2 2026 GDP Growth Forecast at 1.1% Amid Concerns Over Sharp Decline in Household Spending

2026. g. 5. sept. 22:21 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.4% Amid Mixed Economic Signals and Volatile Markets

2026. g. 5. sept. 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Concerns and Global Market Influences Ahead of September Decision.

2026. g. 5. sept. 22:11 UTC

UK Housing Market Sentiment Remains Negative as RICS House Price Balance Forecasts Slight Improvement Amid Broader Economic Concerns

2026. g. 5. sept. 21:51 UTC

South Korea's Unemployment Rate Release on September 8, 2026, Expected Amid Global Job Growth Optimism Following Strong U.S. Data

2026. g. 5. sept. 21:31 UTC

Cautious Market Sentiment Ahead of BRC Retail Sales Monitor YoY Release, Forecasting 1.2% Growth Amid Mixed Economic Signals

2026. g. 5. sept. 21:21 UTC

Spain's Consumer Confidence Index set for release on September 8, with analysts hopeful for improvement amid geopolitical tensions and inflation concerns.

2026. g. 5. sept. 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Trends.

2026. g. 5. sept. 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Recovery Signals.

2026. g. 5. sept. 20:41 UTC

Japan's Current Account Surplus Forecasted at JPY 2,870 Billion Amid Cautious Sentiment from Declining Household Spending

2026. g. 5. sept. 19:21 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Anticipated Amid Geopolitical Tensions and Recent Inventory Volatility.

2026. g. 5. sept. 19:11 UTC

Italy's Industrial Production MoM data for July 2026 set to release on September 10, with a forecasted increase of only 0.3% amid declining trends and mixed signals from Europe.

2026. g. 5. sept. 19:01 UTC

Correlated Moves

Cardano is rising during Saturday's session, supported by Ethereum's performance. The asset is trading above its 20-day moving average, reflecting strong momentum.

2026. g. 5. sept. 18:31 UTC

Swiss Consumer Confidence Index Expected to Remain Low at -32.0 Amidst Cautious Market Sentiment and Global Economic Concerns

2026. g. 5. sept. 18:11 UTC

EUR/SEK is trading roughly flat in after-market hours, showing little change since Friday's close and remaining near the upper end of its one-month range.

2026. g. 5. sept. 18:11 UTC

EUR/CAD is trading roughly flat in after-market hours, showing little change from Friday's close and remaining near the lower end of its one-month range.

2026. g. 5. sept. 18:11 UTC

Turkey's Industrial Production YoY data release on September 10, 2026, may reflect cautious optimism amid recent fluctuations and mixed market sentiment.

2026. g. 5. sept. 17:41 UTC

U.S. Monthly Budget Statement on September 11, 2026, expected to reveal rising deficits amid cautious fiscal sentiment and potential Fed interest rate decisions.

2026. g. 5. sept. 17:41 UTC

France's Industrial Production Expected to Rise 0.3% Amid Cautious Economic Sentiment and Construction Sector Decline

2026. g. 5. sept. 17:31 UTC

UK's Non-EU Goods Trade Balance Report Set for Release on September 11, 2026 Amidst Stable Market Sentiment.

2026. g. 5. sept. 17:31 UTC

UK Monthly GDP Expected to Remain Flat at 0.0% for July Amid Cautious Investor Sentiment and Mixed Economic Signals

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

121.3% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD 121.3%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.